News Detail

Virax Biolabs signs exclusive ImmuneSelect supply deal with Fosun Diagnostics in six Southeast Asian markets

PUBT · 6h ago

Listen to the news

Virax Biolabs signs exclusive ImmuneSelect supply deal with Fosun Diagnostics in six Southeast Asian markets

Virax Biolabs signed an exclusive multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect research-use immune profiling products.
Deal covers Thailand, Vietnam, Indonesia, the Philippines, Singapore, Malaysia; exclusivity tied to minimum purchase and performance terms.
Supply starts immediately under purchase orders, creating near-term revenue potential; pricing includes volume-based tiers.
Initial commercial focus targets tuberculosis-related research demand in Thailand, with potential rollout across other covered markets.
Agreement applies to ImmuneSelect, not the in-development ViraxImmune diagnostic platform.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Virax Biolabs Group Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607090730PR_NEWS_USPR_____DA99533) on July 09, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.

What's Trending

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.